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1 Introduction 
Multiple Sclerosis (MS) is chronic inflammatory demyelinating disease of the central 
nervous system  that affects more than two million young adults worldwide (Weinshenker 
1996). Females are affected more often than males (2,5:1)(Koch-Henriksen and Sorensen 
2010; Niedziela et al. 2014), and the disease usually begins in the second or third decade of 
life. Different disease courses can be distinguished. Most of the patients have a relapsing–
remitting disease course (RRMS), with symptom exacerbation (relapse) over hours to days 
followed by a relapse-free period. Symptoms may regress spontaneously or in response to 
anti-inflammatory corticosteroid therapy. Neurological disability may accumulate during 
the disease course. In later disease stages disability may progress without clinical relapses, 
indicating secondary progressive multiples sclerosis (SPMS). One fifth of the MS patients 
manifest with a progressive disease course from the beginning (primary progressive MS, 
PPMS), with a similar incidence among men and women. Expanded disability status scale 
(EDSS) is used to measure neurological disability in MS. This scale refers to neurological 
findings and ranges from 0 (no impairment) to 10 (death from MS)(Amato and Ponziani 
1999).  
Magnetic resonance imaging (MRI) of the brain serves for diagnosis and differential 
diagnosis of MS.  In MS, it typically shows hyperintense lesions on a T2-weighted (T2W) or 
on fluid attenuation inversion recovery (FLAIR) imaging techniques located 
periventricularly, so-called Dawson’s fingers (Tillema et al. 2013). Intravenous 
administration of the contrast agent gadolinium (Gd) leads to an accumulation of Gd 
within the lesions and indicates blood-brain barrier leakage. In these regions, inflammatory 
cells invade the CNS and inflammatory infiltrates are found. This enhancement is typically 
seen during the first 4-6 weeks after lesion formation and helps to distinguish between old 
and new demyelinating lesion on MRI. (Cotton et al. 2003).   
Dissemination of lesions in space and time must be present to fulfill the diagnostic criteria 
of MS (Polman et al. 2011). A clinical history of two or more attacks in a young adult with 
typical neurological symptoms such as visual problems, paresis or ataxia indicates a 
diagnosis of MS. In case of a single clinical exacerbation, additional MRI should support 
the diagnosis. MRI evidences of dissemination in space (involvement of at least two of the 
following regions: periventricular, cortical or juxtacortical, infratentorial, optic nerve and 
spinal cord) and dissemination in time (new T2 lesion/s or simultaneous presence of 
contrast-enhancing and non-contrast-enhancing lesions) are required for MS diagnosis 
(Filippi et al. 2016). The presence of oligoclonal bands (OCBs) and elevated 
immunoglobulin G (IgG) in the cerebral spinal fluid (CSF) support the diagnosis of MS, 
but are not specific for it (Stangel et al. 2013). 
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1.1 Pathogenesis and histopathological heterogeneity of  multiple 
sclerosis 
Demyelination in MS is generally believed to be caused by pathological immune responses 
to CNS self-antigens; however, the exact mechanism of MS development is unknown. T 
cells, B cells and probably autoantibodies are important factors contributing to MS 
development (Sospedra et al. 2005). Environmental factors such as viral infections 
(especially Epstein-Barr virus), metabolic stress, obesity, smoking and vitamin D deficiency 
in genetically susceptible people may facilitate migration of myelin-specific, auto-reactive 
immune cells across the blood-brain barrier, leading to demyelination, axonal destruction 
and subsequent neurological disability (Shaygannejad et al. 2016). Inflammatory 
demyelinating plaques are characterized by a confluent myelin loss with relative 
preservation of axons and an astrogliosis. Histopathological studies indicate the role of the 
adaptive immune system in disease development, showing that MS lesions contain 
inflammatory cells with CD8+ cytotoxic T cells dominating over CD4+ T helper cells, as 
well as numerous macrophages.  B cells and plasma cells are present in variable numbers. 
Inflammatory cells are typically located around vessels, but also diffusely infiltrate the 
parenchyma. The composition of the immune cell infiltrate and the presence of myelin 
degradation products within the macrophages depend on the stage of the lesional activity 
(Bruck et al. 1995).  
Histological findings also show the heterogeneity of MS lesions and suggest that more than 
one pathogenic mechanism contributes to disease development. Early active demyelinating 
lesions can be classified histopathologically into three immunopathological patterns 
(patterns I-III), suggesting different pathogenic mechanisms that lead to lesion 
development (Lucchinetti et al. 2000). Within a single patient, the immunopathological 
pattern does not change during the disease course (Metz et al. 2014). Patterns I and II share 
similar features of demyelination. In both patterns, T lymphocytes and macrophages 
dominate the lesions. Plaques typically show sharply demarcated lesion borders and in early 
lesions stages, remyelination can often be observed. The only differences between these 
two patterns are immunoglobulin and complement deposits found inside macrophages in 
pattern II. In conclusion, an antibody-mediated mechanism of lesion development may be 
assumed in pattern II. In contrast, pattern III lesions are characterized by the presence of 
apoptotic oligodendrocytes at the lesion edge and a preferential loss of myelin-associated 
glycoprotein (MAG). MAG is a myelin protein located in distal oligodendrocyte processes 
and its loss is considered to be a marker of metabolically stressed oligodendrocytes. Thus, 
changes observed in pattern III lesions possibly reflect primary oligodendrocytic damage 
(Aboul-Enein et al. 2003).  
Introduction 3 
1.2 Apheresis therapy in multiple sclerosis 
Multiple sclerosis cannot be cured, but various drugs are available that can modify the 
disease course (DMDs) and lead to a milder disability. Different treatment approaches are 
used for the therapy during the relapse (acute exacerbations of the disease) and for long-
term therapy. Treatment of the relapse aims to suppress the acute episode of inflammatory 
demyelination in the brain. High-dose glucocorticosteroids (HDCS) are primarily 
recommended for this purpose. In contrast, the long-term therapy is needed to prevent the 
development of new relapses and progression of the disease. For that, several 
immunomodulatory drugs were approved for various MS disease courses. 
Therapeutic plasma exchange (PLEX) and immunoadsorption (IA) are apheresis 
techniques, which are used in MS patients and are recommended by US and European 
neurologists as a second line treatment for MS relapses in case of insufficient response to 
HDCS (Schwartz et al. 2013; Bevan et al.2015). 
The main principle of these methods is to purify the serum of patients from disease-
causing agents such as antibodies/auto-antibodies, immune complexes and cytokines 
(McLeod 2010; Okafor et al. 2010; Williams und  Balogun 2014). During PLEX the serum 
of the patients is replaced with a serum replacement solution, whereas with IA the serum 
passes through the absorber column and is then returned to the blood circulation. 
Apheresis is a second line treatment, and treatment success for the individual patient is not 
predictable. Several retrospective and prospective studies have shown that the efficiency of 
both PLEX and IA for MS relapses is comparable and varies from 40 - 90% (Weinshenker 
et al. 1999, Moldenhauer et al. 2005; Magana et al. 2011; Koziolek et al. 2013; Ehler et al. 
2015). Male sex, early initiation of apheresis treatment and the presence of ring-like, 
contrast-enhancing lesions on MRI are associated with a favorable outcome after 
PLEX/IA treatment (Keegan et al. 2002; Llufriu et al. 2009; Magana et al. 2011).  In 2005, 
Keegan et al. suggested that humoral features could explain the variability in the apheresis 
response in the MS population. Their study proposed that apheresis therapies may be a 
therapeutic option for pattern II patients, which are characterized by immunoglobulin 
deposition and complement activation within lesions (Keegan et al. 2005).  
The aim of the present study was to identify clinical, demographical and histopathological 
parameters that could predict PLEX/IA response in steroid-resistant MS relapses. 
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2 Patients and methods 
This study was approved by the ethics committee of the University Medical Center 
Göttingen (#19/09/10). The study cohort was recruited from our German brain biopsy 
databank, which includes 774 patients nationwide with histologically proven inflammatory 
demyelination consistent with MS. Among those, 386 cases showed an early active 
inflammatory demyelination, classifiable into immunopathological patterns. Sixty-nine 
patients who received apheresis therapy due to a steroid-resistant relapse and who had 
sufficient clinical and radiological information were included in the study. Clinical 
information was obtained from a medical record review (n=69). Treatment response was 
assessed retrospectively and blinded to the histopathologically defined immunopatterns.  
2.1 Clinical and radiological follow-up 
Diagnosis at the time of PLEX/IA was made based on published criteria for MS (Polman 
et al. 2011). The clinical course was classified as single clinical episode (CIS), relapsing-
remitting or secondary-progressive at the time of treatment (Lublin 2014). Index attack was 
defined as the relapse leading to apheresis therapy. The following neurological systems 
were evaluated to assess which deficits occurred with the index attack: consciousness 
(somnolence, sopor, coma), cerebral (e.g. aphasia, apraxia), cognitive (memory dysfunction, 
disorientation), motor, brainstem or cranial nerves, cerebellar, sensory, and bladder/bowel 
dysfunction. Only new or worsening symptoms occurring with the index attack that 
influenced the EDSS score or significantly impacted function were considered.  
Clinical information was extracted from the medical charts before apheresis, including the 
presence of deep tendon reflexes, treatment of the index attack with high/low dose 
corticosteroids (HDCS/LDCS), therapy with DMDs within 3 months before PLEX/IA 
initiation, as well as the CSF cell number, IgG index and presence of OCBs. MRI was 
evaluated for the presence of ring-like, Gd+-enhancing lesions. 
Immunosuppressive/immunomodulatory medications within 30 days after apheresis 
application were noted as well.  
Treatment response was evaluated based on three main outcome parameters. The primary 
outcome was functional changes in the neurological system affected during the relapse. For 
this we used a response evaluation that was published previously (Weinshenker 1999). 
According to this score, none or mild subjective changes in the affected neurological 
system were interpreted as no response, moderate or important gain in neurological status 
were considered to be a treatment response. MRI and EDSS changes were analyzed as 
secondary outcome parameters. Lesions were investigated using T2W images as well as 
Gd-enhanced T1-weighted images (T1W+Gd).  MRI improvement was defined by lesion 
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shrinkage and/or reduction in gadolinium enhancement. EDSS scores were evaluated at 
three time points: 1) last EDSS at relapse-free period before index attack (baseline EDSS), 
2) highest EDSS of index attack before PLEX/IA treatment (EDSS relapse) and 3) EDSS 
within one month after apheresis therapy (EDSS 1 month). EDSS treatment response one 
month after apheresis therapy was defined as a reduction in the EDSS score ≥0.5 points in 
patients with an EDSS score ≥6.0 at the time of index attack, or a reduction ≥1.0 in 
patients with an EDSS ≤ 5.5 before treatment was started ("Guidline on clinical 
inverstigation of medical products for the treatment of multiple sclerosis"  2015).  
2.2 Histopathology and classification of  the lesions 
Histological classification of lesions was performed as described in previous publications 
(Lucchinetti et al. 2000; Metz et al. 2014). For the classification of lesions, first the 
demyelinating activity was determined based on published criteria with early active 
demyelinating lesions containing myelin-laden macrophages immunoreactive both for 
minor and major myelin proteins (Bruck et al. 1995). Those lesions were subsequently 
classified into one of the immunopathological patterns I-III (Lucchinetti et al. 2000). 
Histopathological analysis was performed blinded to PLEX/IA response. 
Tissue sections were analyzed using an Olympus BX41 microscope (Olympus Optical Co, 
Ltd., Hamburg, Germany). Figures were prepared in CorelDraw X3®, version 13.  
2.3 Statistical analyses 
The statistical analysis was performed in cooperation with the Institute of Medical Statistics 
of the University Medical Center Goettingen (David Ellenberger, Prof. Tim Friede, Prof. 
Tim Beissbarth). Descriptive statistics are given for the cohort as a whole and by 
immunopattern strata. These include: frequencies for the categorical outcomes sex, disease 
course, HDCS and DMD treatment, medians (and minimum and maximum) for the 
ordinal outcome EDSS as well as mean (and standard deviation) for the metrical outcomes 
age, PLEX/IA delay (time interval between index attack onset and initiation of PLEX/IA 
treatment), and disease duration (time from first neurological symptoms ever to initiation 
of PLEX/IA treatment). Comparisons for global group differences were made using 
Fisher’s exact test and the Kruskal-Wallis test or the one-way analysis of variance. To adjust 
for relevant covariates the effect of the immunopatterns on treatment response in the 
primary and secondary outcomes were analyzed using logistic regression models. Firth 
correction was used to avoid model fitting problems due to very low response rates in 
some subgroups. Univariate and multivariate effect measures along with penalized 
likelihood profiles-based 95% confidence intervals as well as predicted probabilities for 
various subgroups are given. Selection of relevant covariates was initially done using lasso 
(least absolute shrinkage and selection operator) and subsequently by backward variable 
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selection, eliminating statistically less informative variables to avoid overfitting. Only 
variables that significantly differed between the IP strata were kept permanently in the 
model unless major collinearities appeared. When addressing longitudinal measurements of 
serial PLEX/IA sessions within single patients, generalized estimation equations with a 
compound symmetry covariance structure were used to estimate whether a response is 
predictive for future responses while adjusting for relevant covariates. Statistical analyses 
were carried out with SAS 9.4 and R (Version 3.1.2). In general, two-sided p-values smaller 
than or equal to 5% were regarded as statistically significant. 
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3 Results and Discussion 
3.1 Patient demographics and baseline clinical features 
Apheresis therapies are invasive treatment approaches and are associated with several 
complications, which in some rare cases can be life-threatening.  Among the severe side 
effects are an arterial blood pressure fall, electrolyte imbalance with arrhythmias, hemolysis, 
but also anxiety, vomiting, paresthesias and allergic reactions have been described 
(Szczeklik et al. 2013). On the other hand, 40-90% of patients improve clinically after 
apheresis therapies and thus benefit from this therapeutic option. Therefore, predictors for 
a therapy success would be helpful for decision making in clinical practice. 
In our study we assessed retrospectively different clinical and histological parameters in 69 
patients with histopathologically verified and classified inflammatory demyelinating disease 
compatible with MS, with the aim to find predictors of a PLEX/IA response.  
Demographical, clinical and histological characteristics are summarized in Table 1.  
 
Table 1: Demographic, clinical and histological characteristics of PLEX/IA cohort at the 
time of apheresis treatment 
Demographical, clinical and histological parameters 
 
Sample size n = 69 
Age: mean(sd) 36.6 (13.3) 
Proportion of females (%) 46/69 (66.7%) 
Disease course: Single clinical episode (%) 28/69 (40.6%) 
Disease course: RR (%) 36/69 (52.2%) 
Disease course: SP (%) 5/69 (7.2%) 
Disease duration (years):  median (min, max) 0.2 (0.0,18.0) 
EDSS baseline: median (min, max) 1.0 (0.0,8.5) 
EDSS at index attack: median (min, max) 6.0 (2.0,9.5) 
PLEX/IA delay (days): mean(sd) 25.4 (20.4) 
Therapy with HDCS before PLEX/IA (%) 63/69 (91.3%) 
Therapy with DMD within 3 months before 
PLEX/IA (%) 
17/67 (25.4%) 
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Immunopathological pattern I 16/69 
Immunopathological pattern II 40/69 
Immunopathological pattern III 13/69 
Abbreviations: RR: relapsing remitting; SP: secondary progressive; EDSS: expanded disability status 
scale; PLEX: plasma exchange; IA: immunoadsorption; HDCS: high dose of corticosteroids; DMD: 
disease modifying drugs, sd: standard deviation, min: minimum, max: maximum.  
 
At the time of apheresis therapy, more than two-thirds of the patients (74%; n=51) had 
clinically definite MS according to the 2011 McDonald criteria. Ten patients had a single 
clinical episode (one relapse), but fulfilled the McDonald criteria for MS diagnosis. About 
one fifth of the patients (16/69, 23%) showed histological characteristics of early active 
inflammatory demyelinating lesions consistent with immunopathological pattern I. More 
than a half of the patients (40/69, 58%) were diagnosed histopathologically with 
immunopathological pattern II and 19% (13/69) of the patients showed histopathological 
features of pattern III. 
The median number of PLEX exchanges/IAs was 5.0, the therapeutic regimen being 
determined by the treating physician. IA was performed in 15% of patients (n=10). Three 
of those patients had combined PLEX and IA treatments. Most of the patients received 
high dose corticosteroids (91%; n=63) and one fourth (25%; n=17) DMDs within 3 
months before PLEX/IA application.  
3.2 Response to apheresis treatment 
Treatment response was evaluated within 30 days after the PLEX/IA application and was 
based on the main outcome parameters: functional improvement, MRI and EDSS response 
(see Methods). Thirty-nine percent of the patients showed functional (27/69) and/or MRI 
(18/46) improvement after PLEX/IA treatment. This percentage is consistent with 
published data of 40-90% (Weinshenker et al. 1999, Magana et al. 2011). EDSS response 
rate was 28% (19/67) and thus lower as compared to the functional response observed 
(Figure 1). Due to EDSS insensitivity to the changes of the function of upper extremities 
or cognition, six patients with functionally important improvement did not showed 
changes in the EDSS (Meyer-Moock S et al. 2014).  
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Figure 1: Functional, MRI and EDSS response to the apheresis therapy  
The percentage of the patients with functional (moderate or marked functional improvement), MRI 
(lesions that were shrunk and/or showed less contrast enhancement) and EDSS (EDSS 
improvement ≥ 0.5 in patients with EDSS score ≥ 6.0 and an EDSS improvement ≥ 1.0 in patients 
with EDSS score ≥ 5.5) response.  
However only 3% (2/27) of the patients showed a complete recovery after the treatment. 
Most patients still had residual deficits in the system that were affected during the index 
attack, and 84% presented with multifocal neurological deficits involving more than one 
functional system. Index attack symptoms leading to PLEX/IA treatment are shown in 
Figure 2. Motor dysfunction (75% of patients) and brainstem involvement (57%) were the 
most frequently targeted neurological systems (Figure 2). 
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Neurological systems affected. Data are presented as the percentage of patients with affection of 
the specified functional system in relation to all patients. Most of the patients presented with a 
polysymptomatic index attack and thus have more than one neurological system affected.  
A clinical improvement could be observed in most functional systems (Figure 3). The 
highest response rate was evident for the functional system consciousness (42%, n=5/12) 
and the cerebellar system (43%, n=6/14), followed by the cognitive (30%, n=6/20) and 
motor systems (29% n= 14/49).  
  
Figure 3: Functional response to apheresis therapy stratified to different neurological 
systems 
Data are presented as the percentage of patients with improvement of the specified functional 
system in relation to all patients with this functional system affected. For some patients, clinical data 
were not sufficient to judge therapy response in single functional systems.  
In summary, our data show similar clinical response rates to apheresis therapies as in 
previously published MS cohorts. 
3.3 Predictors of  the apheresis response.  
Next we used multifactorial logistic regression analysis to identify demographical, clinical 
and histopathological parameters that could predict a PLEX/IA response.  Previous 
studies reported that male sex, preserved reflexes, early initiation of the treatment and 
lower baseline EDSS were associated with better treatment outcome (Keegan et al. 2002; 
Llufriu et al., 2009; Ehler et al.). Additionally we analyzed index attack-related symptoms, 
disease severity, histopathological patterns, MRI parameters as well as CSF variables in 
univariate and multivariate logistic regressions (Figure 4).  
Four parameters came out to be positive predictive factors during this analysis: These are 
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5.61, 95% CI: 2.49-11.32, p<0.001), as well as application of the IA compared to PLEX 
(logOR: 3.26, 95% CI: 0.75-8.1, p=0.008) and, with a lower effect size, new cognitive 
deficits at the time of index attack. (logOR: 1.56, 95% CI: 0.03-4.37, p=0.046). In contrast, 
involvement of the brainstem and cranial nerves emerged as negative predictive factors 

















Figure 4: Logistic regression model of the PLEX/IA response  
Effect estimates on functional response to apheresis therapy: The estimated log odds ratio of 
relevant covariates including penalized likelihood profiles-based 95% confidence intervals are given 
on whether patients experienced a moderate or marked functional improvement after PLEX/IA 
treatment. Covariates with a negative log odds ratio predict no therapy response, covariates with a 
positive log odds ratio predict therapy success. Covariate estimates are significant when the 95% 
confidence interval does not cross the log odd ratio 0. Estimates were obtained by multivariate 
logistic regression using Firth correction. Estimates indicate patterns I and II, affection of the 
cognitive system and therapy with immunoadsorption as covariables associated with a therapy 
success, with the pattern II showing the highest log odds ratio. Estimates suggest that brainstem 
affection is associated with a treatment failure. Multivariate (or more precisely, ‘multivariable’) 
adjustment included the following covariates: immunopattern, affection of the neurological systems 
brainstem or cognitive functions, therapy with immunoadsorption and disease duration as well as 
delay of PLEX/IA treatment. The covariable CSF cell count is shown logarithmized. 
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Abbreviations: RR disease course: relapsing–remitting disease course; SP disease course: secondary 
progressive disease course; HDCS: high-dose corticosteroids; DMD: disease-modifying drug;   
EDSS: expanded disability status scale; PLEX: plasma exchange; IA: immunoadsorption; CSF: 
cerebral spinal fluid; IgG: immunoglobulin G. Reproduced with permission from JAMA Neurology 
2018, 75(4): 428-435. Copyright© (2018) American Medical Association. All rights reserved. 
 
Estimating predicted probability we found out that the highest probability for the therapy 
response was in pattern II patients with no brainstem involvement who were treated with 
IA (99 %; Table 2), whereas the lowest probability of a therapy response was in a pattern 
III patient with brainstem and cranial nerve involvement (0%, Table 2). It should be noted 
that in peripheral subgroups, the predicted therapy response rate might be overfitted.  
Table 2: Predicted probability of therapy response to apheresis treatments stratified by 
immunopathological patterns, brainstem involvement and affection of the cognitive 
functions at index attack 
 
The predicted percentage of patients responding to apheresis treatment and 90% confidential 
interval are given. In peripheral subgroups the predicted therapy response rate might be overfitted.  
Abbreviations: IA: immunoadsorption, PLEX: plasma exchange, Brainstem - : Brainstem not 
affected at index attack, Brainstem +: Brainstem affected at index attack. Cognition -: Cognitive 
function not affected at index attack, Cognition +: Cognitive function affected at index attack. 
Reproduced with permission from JAMA Neurology 2018, 75(4): 428-435. Copyright© (2018) 
American Medical Association. All rights reserved. 
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The study of Keegan et al. analyzed the PLEX response with respect to histopathologically 
determined immunopathological patterns (Keegan et al. 2005). Of their 19 patients, only 
patients with pattern II pathology responded to PLEX treatment, but none of the patients 
with pattern I or III pathology. Thus, their study proposed that apheresis therapy is 
exclusively effective in pattern II patients, which are characterized by immunoglobulin 
deposition and complement activation within lesions. This is in line with the known 
efficacy of apheresis therapies in antibody-mediated diseases such as neuromyelitis optica 
(NMO) or myasthenia gravis (Gajdos et al. 2002; Kim et al. 2013; Yamada et al. 2015). In 
our study analysing a larger cohort of 69 patients, both immunopathological pattern I and 
II turned out to be positive predictive factors for an apheresis response (see also 3.4 for 
discussion). 
In studies of myasthenia gravis, IA was associated with less severe side effects as compared 
to PLEX (Köhler et al. 2011).  The previous studies in MS patients showed a significant 
clinical improvement after IA in 73-85% of MS patients compared to 40-70% after PLEX, 
indicating a similar efficacy (Koziolek et al. 2013, Schimrigk et al. 2016).  Faissner et al, 
showed in a series of 48 patients that the combination of both PLEX and IA may be more 
effective than when only one of the treatments is applied alone (Faissner et al. 2016). 
However, controlled data comparing clinical efficacy of both methods in a clinical study are 
lacking. Our study was limited by the low number of patients treated with IA (n=10), so 
that further studies are necessary to explore whether IA may even have treatment effects 
superior to PLEX. Interestingly, IA not only removes antibodies but also other proteins 
such as complement factors, MBP, CD5L, transthyretin, serum amyloid P, that may be 
involved in MS pathogenesis (Koziolek et al. 2012).  
Brainstem affection was observed here to be a negative predictive factor for therapy 
response. Prior studies, however, did not find such an association (Magana et al. 2011; 
Meca-Lallana et al. 2013). Some radiological studies have shown that patients with 
brainstem involvement had a worse prognosis, regardless of apheresis therapy (Trojano et 
al. 1995; Tintore et al. 2010). In this study, clinical involvement of the brainstem was not 
always accompanied by brainstem lesions on MRI. Thus, clinical brainstem involvement 
should be considered as a potential factor negatively influencing therapy response. 
Previous studies reported that lesions with edema, mass effect and ring-like enhancement 
on MRI were associated with a beneficial therapy response to PLEX (Magana et al. 2011). 
The radiological appearance of a lesion reflects its pathological features. Ring-like 
enhancement is found in pattern I and pattern II lesions and correlates with a macrophage 
rim at the lesion border (Bruck et al. 2001). Therefore, ring-like enhancement on MRI 
could be helpful for predicting treatment response. Although a ring-like contrast 
enhancement was found significantly more often in pattern II than in pattern III patients 
(none of the pattern III patients showed ring enhancement), it was not independently 
associated with a favorable outcome. This may be due to the limited number of patients 
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with available MRIs and ring-like contrast enhancement in our study (n=16). Other 
previously reported clinical (early initiation of treatment, shorter disease duration, 
preserved deep tendon reflexes, baseline EDSS < 5.0) and demographic factors (male sex) 
associated with an apheresis therapy response could not be confirmed in the present study.  
3.4 Mechanism of  action of  the apheresis therapy in three 
immunopathological patterns   
Histological classification of the patients with early active demyelinating lesions turned out 
to be important for apheresis response prediction. The histopathological differences 
among the lesion are intraindividually stable and reflect the pathophysiological mechanism 
of lesion development (Lucchinetti et al. 2000; Metz et al. 2014). Pattern I and II share 
similar histopathological features. In these patterns inflammatory mechanisms seems to 
play the main role in lesion development. These patterns are only distinguishable from each 
other by the immunoglobulins and complement deposits along the myelin sheaths and 
within the macrophages observed in pattern II, suggesting an antibody/complement-
mediated demyelination. However, specific pathogenic autoantibodies in MS patients could 
not yet be identified, although MOG-IgG antibodies may be pathogenic in a low 
percentage of adult pattern II patients (Konig et al. 2008; Di Pauli et al. 2015; Spadaro et al. 
2015; Jarius et al. 2016).  
Due to our findings we focused on the efficiency of apheresis therapies in MS patients 
stratified according to their pattern of early demyelination.  Demographic data as well as 
clinical baseline characteristics stratified by immunopathological patterns are summarized 
in Table 3. Groups showed no statistically significant differences in most demographical 
and clinical parameters listed. However, disease course, time intervals between the start of 
the index attack and the apheresis therapy (PLEX/IA delay) and disease duration (time 
interval from first symptoms ever up to apheresis therapy) were different between the 
groups. To exclude possible influences of these parameters on primary and secondary 
outcome measures, analyses were corrected for these variables. 
Table 3: Demographic and clinical characteristics of PLEX/IA cohort at the time of 
apheresis treatment stratified to the immunopathological pattern of MS lesions 
 
Pattern I Pattern II Pattern III p-value 
Sample size n = 16 n = 40 n = 13 
 
Age: mean(sd) 35.3 (13.1) 38.4 (13.9) 32.7 (11.3) 0.376 
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Disease course: Single 














Disease course: SP (%) 1/16 (6.2%) 3/40 (7.5%) 1/13 (7.7%) 1.000 
Disease duration 









EDSS baseline: median 
(min, max) 
0.0 (0.0,6.5) 2.0 (0.0,8.5) 0.0 (0.0,8.5) 0.198 
EDSS at index attack: 
median (min, max) 
7.5 (3.5,9.5) 5.0 (2.0,9.5) 6.0 (3.0,9.0) 0.120 
PLEX/IA delay (days): 
mean(sd) 
16.3 (13.6) 26.5 (22.8) 33.2 (16.1) 0.074 
Therapy with HDCS 
before PLEX/IA (%) 
13/16 
(81.2%) 
37/40 (92.5%) 13/13 (100.0%) 0.192 
Therapy with DMD 








Abbreviations: RR: relapsing remitting; SP: secondary progressive; EDSS: expanded disability status 
scale; PLEX: plasma exchange; IA: immunoadsorption; HDCS: high dose of corticosteroids; DMD: 
disease-modifying drugs, sd: standard deviation, min: minimum, max: maximum. p-values < 10% 
are printed in bold. Reproduced with permission from JAMA Neurology 2018, 75(4): 428-435. 
Copyright© (2018) American Medical Association. All rights reserved. 
 
The same three main outcome parameters (functional improvement, MRI and EDSS 
responses) were applied in this analysis. The highest response rate with 55% was found in 
pattern II patients (22/40 patients), fitting partially to the findings from Keegan et al. 2005 
with a response rate of 100% in pattern II patients. In addition, we could show that every 
third patient with pattern I pathology (5/16 patients; pattern I vs pattern III p=0.03) also 
responded to the PLEX/IA therapy. Patients with pattern III (0/13; p<0.001) lesions did 
not show any treatment response. Approximately the same picture was observed by 
analyzing MRI improvement as an outcome parameter. Pattern II patients showed more 
often a lesion regression (56%; n=14/25) compared to pattern III patients (11%; n=1/9; 
p=0.03). In pattern I patients, lesion improvement was observed in 25% of patients 
(n=3/12).  EDSS response again was highest in pattern II (40%; 15/38) followed by 
pattern I (25%; 4/16) patients. None of the patients with a pattern III showed an EDSS 
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improvement (0/13, Figure 5). These differences remained statistically significant after 
adjustment for the covariables disease duration, PLEX/IA delay, affection of the brainstem 
or cognitive system and therapy with immunoadsorption in a logistic regression model. 
 
 
Figure 5: Functional, MRI and EDSS responses to apheresis therapies stratified according 
to immunpathological patterns of MS lesions. 
The percentage of patients with functional (moderate or marked functional improvement), MRI 
(lesions that shrunk and/or showed less contrast enhancement) and EDSS (EDSS improvement ≥ 
0.5 in patients with EDSS score ≥ 6.0 and an EDSS improvement ≥ 1.0 in patients with EDSS 
score ≥ 5.5) response is shown.  
Nonspecific removal of antibodies and circulating immune complexes is suggested as a 
mechanism of action of apheresis therapies in pattern II patients. Apheresis therapies have 
been shown before to be beneficial in CNS antibody-mediated diseases such NMO and 
NMDA (N-methyl-D-aspartate) receptor encephalitis. Apheresis therapies reduce serum 
antibodies by 85% compared to pre-apheresis levels (Kim et al. 2013; Kleiter et al. 2016). 
In pattern I lesions, proinflammatory mediators such as cytokines and chemokines 
produced by activated microglia/macrophages and T cells were suggested to cause myelin 
damage (Popescu et al. 2013). Elimination of cytokines, soluble cytokine receptors, 
adhesion molecules or complement factors from plasma may thus be beneficial in pattern I 
patients, but data on the removal of these substances with PLEX are controversial (Reeves 
and  Winters 2014). Cytokine levels were not lowered after PLEX in septic patients 
(Hamishehkar et al. 2013). In contrast, a reduction in interleukin 8 (IL8) and tumor 
necrosis factor α (TNF-α) cytokine levels was observed after PLEX therapy for thrombotic 
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(Shariatmadar et al. 2005). Levels of soluble intracellular adhesion molecular 1 (ICAM-1) 
and vascular cell adhesion molecule 1 (VCAM-1) decreased after PLEX for myasthenia 
gravis (Tesar et al. 2000). Fibrinogen and C3 were reduced in plasma after PLEX for MS 
relapses (Weiner et al. 1989). Thus, elimination of factors other than antibodies may be 
relevant for the treatment effects of apheresis therapies observed in about one third of 
patients with pattern I pathology.   
In addition to the removal of pathological agents, changes in immune cell numbers, 
composition and activation after apheresis treatment can also be observed. In patients with 
Guillain-Barré syndrome, B cell numbers decreased and T cells, particularly CD4+ T cells, 
increased after apheresis treatment, resulting in a normalization of cell subsets (Yoshi and  
Shinohara 2000). Suppressor functions of T helper cells increased after PLEX/IA in 
patients with chronic inflammatory demyelinating polyneuropathy (CIDP) to a level of 
healthy controls (De Luca et al. 1999). A shift in the balance of Th1/Th2 T cells was also 
described after PLEX treatment (Soltesz et al. 2002). Changes may occur either due to 
alterations in concentrations of soluble plasma factors, or due to the apheresis procedure 
itself: HLA (human leukocyte antigen)-I molecules adsorbed on the polymer membrane or 
absorber column may modulate the immune response of T lymphocytes and neutrophils 
during their bypass, resulting in their activation (Ghio et al. 2014). Although studies have 
not been performed in MS patients, immune cell alterations may also be relevant for the 
reduction of inflammatory activity in MS after apheresis treatments.  
In contrast, the histopathology of pattern III lesions resembles white matter stroke, and the 
mitochondrial changes described in these lesions suggest a hypoxia-like tissue injury rather 
than an inflammation-driven pathogenesis (Mahad et al. 2008). This might explain the non-
response to PLEX/IA treatment.  
Fourteen patients received more than one PLEX/IA session. With the use of generalized 
estimation equations, longitudinal measurements of therapy responses to consecutive 
PLEX/IA sessions within one patient were not positively correlated (rho = -0.269). This 
means that prior therapy response in pattern I and II patients did not predict therapy 
response in later sessions. Patients with pattern III did not respond to either the first or the 
following PLEX/IA session. 
3.5 Conclusions 
In conclusion, this study shows that histopathological patterns I and II, involvement of the 
cognitive system with the clinical relapse, as well as application of IA could help to predict 
a therapy success with apheresis therapies in MS patients with steroid-resistant relapses. In 
contrast, brainstem involvement and histological features of immunopathological pattern 
III were negative predictive factors.  Differences in the response to PLEX/IA comparing 
the immunopathological patterns I-III of MS lesions elucidates the potential mechanism of 
action of apheresis therapies, and may at least in part explain differences in the apheresis 
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response among MS patients. Importantly, if an apheresis treatment was not successful for 




Plasma exchange and immunoadsorption are second-line apheresis therapies for steroid-
unresponsive multiple sclerosis relapses with a variable response rate. The mechanism of 
action of these therapies is assumed to be the removal of disease-causing agents such as 
antibodies, immune complexes and cytokines. A retrospective analysis of different 
demographical, clinical and histological parameters, which potentially could predict 
responses to apheresis therapies, was performed in 69 patients with multiple sclerosis 
lesions classified into pathological patterns I-III. The primary therapy outcome parameter 
was a functionally relevant improvement of the relapse-related neurological deficit. 
Radiological and expanded disability status scale changes were secondary outcome 
parameters.  
We found that immunopathological patterns I and II, as well as application of 
immunoadsorption and involvement of the cognitive function with the relapse were 
positive predictive factors for a functional therapy response. In contrast, 
immunopathological pattern III and brainstem involvement with the relapse were negative 
predictive factors. A functional therapy response was observed in 31% (5/16) of pattern I 
and 55% (22/40) of pattern II patients, whereas no improvement was found in pattern III 
patients (0/13, p<0.001 pattern II versus III). Radiological findings supported the primary 
outcome. Lesion improvements were found in 25%, 56% and 11% of patterns I, II and III, 
respectively. The expanded disability status scale response rates again showed highest 
success rates in pattern II patients (40%) and were 25% and 0% for patients with patterns I 
and III.  
Our results show that the response to apheresis treatment could be predicted by 
immunopathological patterns as well as involvement of the cognitive and brainstem 
systems. Potentially, IA is more effective than PLEX, but this has to be clarified in further 
studies. Different pathological subtypes of early active multiple sclerosis lesions suggests 
different pathophysiological mechanism of lesion development and thus may explain the 
varying therapy responses.  Pattern I and II lesions show sharp lesion edges and an 
infiltration with T-cells and macrophages. Additionally, an antibody and complement-
mediated mechanism of demyelination is suggested in pattern II. These patients also 
showed the most success from the apheresis treatment. In contrast, in pattern III lesions a 
primary oligodendrocytic damage may play an important role in lesion pathogenesis; 
patients showing this pattern are not amenable to apheresis treatments.  
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5 Supplementary material 
The doctoral thesis was written based on the following original publication: 
Stork L, Ellenberger D, Beißbarth T, Friede T, Lucchinetti C, Brück W, Metz I (2018): 
Differences in the responses to apheresis therapy of patients with 3 histopathologically 
classified immunopathological patterns of multiple sclerosis.  JAMA. Neurol 75, 428-435.   
To read the article please follow the link: 
doi:10.1001/jamaneurol.2017.4842 
 
This article received an acknowledgement from the editor Robert J. Fox 
Fox RJ (2018): Tissue markers for the acute multiple sclerosis treatment response – a step 
towards personalized medicine.  JAMA Neurol 75, 406-407. 
To read this editorial please follow the link: 
doi:10.1001/jamaneurol.2017.4850 
 
Lidia Stork and Imke Metz also received an Apheresis Innovation Award from the 
German nephrological society for this study.
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